Response to Letter to the Editor: Pharmacokinetic Variability in Anti‐TFPI Therapies: Why Absolute Metrics Matter for Plasma Monitoring
Haemophilia · 2026-11 · 32 (6) · 1554-1555
DOI: 10.1111/hae.70369 ↗Kurz gefasst
Leserbrief in der Zeitschrift Haemophilia, online erschienen am 22.08.2026. Verfasst von Travis Gould und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., New York, New York, USA. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Why Absolute Metrics Matter for Plasma Monitoring by López et al. which reports pharmacokinetic parameters of two anti-TFPI agents, marstacimab and concizumab [ 1 ].We have identified several potential inaccuracies and factual errors within the article, and we believe it is important to clarify these points for the scientific community.Our concerns can be consolidated into two main themes: computational inaccuracies in the presentation of key data and a lack of methodological transparency regarding primary data sources.
Autor:innen und Institutionen
- Pfizer Inc., New York, New York, USA.
- Pfizer Inc., Collegeville, Pennsylvania, USA.
Zitieren
APA
Gould, T., Raje, S., & Kim, H. K. (2026). Response to Letter to the Editor: Pharmacokinetic Variability in Anti‐TFPI Therapies: Why Absolute Metrics Matter for Plasma Monitoring. Haemophilia, 32(6), 1554-1555. https://doi.org/10.1111/hae.70369
Vancouver
Gould T, Raje S, Kim HK. Response to Letter to the Editor: Pharmacokinetic Variability in Anti‐TFPI Therapies: Why Absolute Metrics Matter for Plasma Monitoring. Haemophilia. 2026;32(6):1554-1555. doi:10.1111/hae.70369
BibTeX
@article{Gould2026,
author = {Gould, Travis and Raje, Sangeeta and Kim, Hae Kyung},
title = {Response to Letter to the Editor: Pharmacokinetic Variability in Anti‐TFPI Therapies: Why Absolute Metrics Matter for Plasma Monitoring},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {6},
pages = {1554--1555},
doi = {10.1111/hae.70369}
}
EUVIMED